KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $3.62 $5.09 Friday, 26th Apr 2024 RLMD stock ended at $3.83. This is 3.51% more than the trading day before Thursday, 25th Apr 2024. During the day the stock fluctuated 6.91% from a day low at $3.62 to a day high of $3.87.
90 days $3.55 $7.22
52 weeks $2.36 $7.22

Historical Relmada Therapeutics, Inc. prices

Date Open High Low Close Volume
Apr 26, 2024 $3.69 $3.87 $3.62 $3.83 80 013
Apr 25, 2024 $3.79 $3.80 $3.66 $3.70 85 395
Apr 24, 2024 $3.95 $3.96 $3.75 $3.86 114 573
Apr 23, 2024 $3.91 $4.10 $3.82 $3.91 143 631
Apr 22, 2024 $3.99 $4.06 $3.70 $3.87 177 963
Apr 19, 2024 $4.30 $4.31 $3.95 $4.00 152 601
Apr 18, 2024 $4.65 $4.72 $4.27 $4.30 86 051
Apr 17, 2024 $4.62 $4.72 $4.52 $4.68 85 105
Apr 16, 2024 $4.47 $4.61 $4.32 $4.56 63 014
Apr 15, 2024 $4.67 $4.73 $4.41 $4.45 125 004
Apr 12, 2024 $4.61 $4.68 $4.54 $4.65 120 017
Apr 11, 2024 $4.60 $4.81 $4.50 $4.66 116 503
Apr 10, 2024 $4.77 $4.90 $4.29 $4.51 158 376
Apr 09, 2024 $4.92 $5.09 $4.75 $4.80 87 624
Apr 08, 2024 $4.64 $4.97 $4.64 $4.86 63 172
Apr 05, 2024 $4.72 $4.84 $4.53 $4.59 101 079
Apr 04, 2024 $4.75 $5.02 $4.66 $4.69 177 297
Apr 03, 2024 $4.96 $5.09 $4.68 $4.71 144 595
Apr 02, 2024 $4.97 $5.05 $4.79 $4.94 136 502
Apr 01, 2024 $4.65 $5.00 $4.60 $4.88 126 407
Mar 28, 2024 $4.62 $4.65 $4.50 $4.65 113 100
Mar 27, 2024 $4.87 $4.87 $4.40 $4.59 149 728
Mar 26, 2024 $4.97 $5.00 $4.64 $4.69 102 444
Mar 25, 2024 $4.80 $5.13 $4.68 $4.90 271 389
Mar 22, 2024 $4.61 $4.95 $4.54 $4.86 267 361
Click to get the best stock tips daily for free!

About Relmada Therapeutics, Inc.

Relmada Therapeutics. Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder ... RLMD Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT